GSK Announces Groundbreaking $1.15 Billion Acquisition of IDRx to Revolutionize GIST Treatment

GSK plc has agreed to acquire IDRx, Inc. for up to $1.15 billion, including a highly selective KIT tyrosine kinase inhibitor, IDRX-42, for GIST treatment, promising to address a si...